MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $36.30 | Prev. Close $41.98 | Circuit Range N/A |
Day Range $36.30 - $42.88 | Year Range $4.81 - $42.88 | Volume 43,471 |
Average Traded $40.13 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
14-Jan-26 | $36.30 | $42.56 | +0.00% |
14-Jan-26 | $36.30 | $42.56 | +16.67% |
12-Jan-26 | $31.73 | $36.48 | +15.01% |
09-Jan-26 | $31.01 | $31.72 | +3.24% |
08-Jan-26 | $31.86 | $30.73 | -5.56% |
07-Jan-26 | $30.13 | $32.53 | +13.12% |
06-Jan-26 | $29.72 | $28.76 | -1.91% |